Q-omics provides the consensus-scored MYLK3 profile across patient tissues and cancer cell-line models. MYLK3 expression is associated with patient survival in 27 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, MYLK3 is differentially expressed in 11, with the highest sampling consensus in KIRC. Additionally, MYLK3 RNA expression shows 17,451 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight ACC, KIRC, and THYM as cancer lineages where MYLK3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MYLK3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MYLK3 survival associations across molecular data types. MYLK3 RNA expression shows survival associations in the most cancer types (27), followed by mutation status (11) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MYLK3 RNA expression–survival associations across cancer types. High MYLK3 expression shows unfavorable associations in LUSC, BRCA and BLCA, but favorable associations in ACC, LGG and UCEC. The ACC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for MYLK3 RNA expression.
This table summarizes MYLK3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 4. The strongest signals are observed in KIRC for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for MYLK3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MYLK3 shows lower tumor expression in KIRC, KIRP, HNSC, LUAD, KICH and LUSC. The KIRC box plot shows higher MYLK3 RNA expression in normal versus tumor tissue (log2 FC = −1.235, t-test p < 0.001).
This table shows molecular features associated with MYLK3 in patient tissues and cancer cell lines. In patient samples, MYLK3 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, MYLK3 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_SCLC, while CRISPR and shRNA rows add functional-dependency signals in CNS and LARGE_INTESTINE.
